Ignite Creation Date:
2024-05-05 @ 5:03 PM
Last Modification Date:
2024-10-26 @ 9:27 AM
Study NCT ID:
NCT00371670
Status:
COMPLETED
Last Update Posted:
2017-03-28
First Post:
2006-08-31
Brief Title:
SafetyEfficacy of Balicatib AAE581 in Adults With Osteoarthritis of the Knee
Sponsor:
Novartis Pharmaceuticals
Organization:
Novartis
Study Overview
Official Title:
A Phase II 12-month Double-blind Placebo-controlled Dose-finding Multicenter Study to Evaluate the Safety Tolerability and Disease Modifying Efficacy of Daily Oral AAE581 10 25 and 50 mg Tablets in Patients With Painful Knee Osteoarthritis Kellgren-Lawrence Grade 3 by X-ray
Status:
COMPLETED
Status Verified Date:
2017-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study will test efficacy and safety of AAE581 compared to placebo in limiting cartilage loss in patients with painful knee osteoarthritis which is confirmed by X-ray
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None